pubmed-article:8642263 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0014644 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0085112 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0004561 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0522537 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0684321 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
pubmed-article:8642263 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
pubmed-article:8642263 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:8642263 | pubmed:dateCreated | 1996-7-16 | lld:pubmed |
pubmed-article:8642263 | pubmed:abstractText | C.B-17 scid/scid (severe combined immunodeficiency [SCID]) mice inoculated with peripheral blood lymphocytes from Epstein-Barr virus (EBV)-seropositive donors, or with EBV-transformed lymphoblastoid B cell lines (EBV-LCL), develop lethal human EBV+ B cell lymphoproliferative disorders (EBV-LPD) with characteristics similar to those arising in immunodeficient patients. Using this model, we examined the capacity of human effector cells to control human EBV-LPD. SCID mice received rabbit anti-asialo GM1 antiserum to abrogate endogenous natural killer-cell function. Preliminary experiments showed that adoptive transfer of peripheral blood mononuclear cells (PBMC), purified T cells, interleukin (IL) 2-activated PBMC or anti-CD3-activated T cells derived from EBV-seropositive donors did not result in improved survival of treated mice (in vivo effector/target ratio 2:1 to 1:1). In contrast, EBV-specific cytotoxic T lymphocytes (CTL), derived from EBV-seropositive donors and expanded in vitro, exhibited strong EBV-specific and HLA-restricted activity both in vitro and in vivo. SCID mice inoculated intraperitoneally with autologous but not with HLA-mismatched EBV-LCL had significantly improved survival relative to untreated mice after inoculation of EBV-specific CTL either intraperitoneally (P<0.001) or intravenously (P<0.001) (in vivo effector/target ratio 1:1). SCID mice bearing large subcutaneous EBV+ tumors and treated intravenously with 10(7) EBV-specific CTL achieved complete tumor regression. Both CTL- and CTL-plus-IL-2-treated mice survived significantly longer than untreated animals or animals treated with IL-2 alone (P = 0.0004 and P<0.02, respectively). SCID mice bearing two subcutaneous EBV+ tumors, one autologous and the other HLA mismatched to the EBV-specific CTL donor, had regression of only the autologous tumor after intravenous infusion of 10(7) EBV-specific CTL. Moreover, we could demonstrate preferential homing of PKH26-labeled EBV-specific CTL to autologous but not to HLA-mismatched EBV+ tumors as early as 24 h after intravenous adoptive transfer. Immunophenotypic analyses also demonstrated preferential infiltration of T cells into the autologous EBV+ tumor in SCID mice bearing both the autologous and either fully HLA-mismatched or genotypically related haplotype-sharing EBV+ tumors. The human T cells infiltrating EBV+ tumors were CD3+ and, predominantly, CD8+CD4-. Our results indicate that EBV-specific CTL preferentially localize to and infiltrate EBV+ tumors bearing the appropriate HLA antigens and thereafter induce targeted regressions of disease. | lld:pubmed |
pubmed-article:8642263 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:language | eng | lld:pubmed |
pubmed-article:8642263 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8642263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8642263 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8642263 | pubmed:month | Mar | lld:pubmed |
pubmed-article:8642263 | pubmed:issn | 0022-1007 | lld:pubmed |
pubmed-article:8642263 | pubmed:author | pubmed-author:O'ReillyR JRJ | lld:pubmed |
pubmed-article:8642263 | pubmed:author | pubmed-author:FernandezJ... | lld:pubmed |
pubmed-article:8642263 | pubmed:author | pubmed-author:LouieD CDC | lld:pubmed |
pubmed-article:8642263 | pubmed:author | pubmed-author:LadanyiMM | lld:pubmed |
pubmed-article:8642263 | pubmed:author | pubmed-author:PapadopoulosE... | lld:pubmed |
pubmed-article:8642263 | pubmed:author | pubmed-author:LacerdaJ FJF | lld:pubmed |
pubmed-article:8642263 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8642263 | pubmed:day | 1 | lld:pubmed |
pubmed-article:8642263 | pubmed:volume | 183 | lld:pubmed |
pubmed-article:8642263 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8642263 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8642263 | pubmed:pagination | 1215-28 | lld:pubmed |
pubmed-article:8642263 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |
pubmed-article:8642263 | pubmed:meshHeading | pubmed-meshheading:8642263-... | lld:pubmed |